Search Within

Omar Ibrahim Abdel-Wahab

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (37)
  2. Meeting Abstract (21)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (59)
  2. Department of Medicine (59)
  3. Epidemiology and Biostatistics (59)
  4. Executive Committee, Center for Hematologic Malignancies (59)
  5. GSK Faculty (59)
  6. Hematologic Malignancies, Division of (59)

More Groups

People
  1. Ross Levine (28)
  2. Martin Tallman (24)
  3. Mithat Gonen (21)
  4. Eytan Stein (13)
  5. Mikhail Roshal (11)
  6. Ahmet Dogan (10)

More People

Years
  1. 2024 (2)
  2. 2023 (11)
  3. 2022 (6)
  4. 2021 (5)
  5. 2020 (5)
  6. 2019 (4)

More Years

Publications
  1. Blood (20)
  2. Blood Advances (4)
  3. British Journal of Haematology (4)
  4. Leukemia (3)
  5. Leukemia Research (2)
  6. Nature (2)

More Publications

Publishers
  1. American Society of Hematology (24)
  2. Nature Publishing Group (10)
  3. John Wiley & Sons (4)
  4. Elsevier Science, Inc. (3)
  5. Massachusetts Medical Society (3)
  6. American Association for the Advancement of Science (2)

More Publishers

Results (59)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia
    Journal Article

    Shahid, S.; Ceglia, N.; Le Luduec, J. B.; McPherson, A.; Spitzer, B.; Kontopoulos, T.; Bojilova, V.; Panjwani, M. K.; Roshal, M.; Shah, S. P.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
    Journal Article

    Stahl, M.; Derkach, A.; Farnoud, N.; Bewersdorf, J. P.; Robinson, T.; Famulare, C.; Cho, C.; Devlin, S.; Menghrajani, K.; Patel, M. A.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Immune escape after allogeneic hematopoietic cell transplantation in pediatric patients with acute myeloid leukemia
    Meeting Abstract

    Shahid, S.; Ceglia, N.; Le Luduec, J. B.; McPherson, A.; Spitzer, B.; Bojilova, V.; Panjwani, M. K.; Roshal, M.; Shah, S.; Abdel-Wahab, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase II clinical trial of E7820 for patients with relapsed/refractory myeloid malignancies with mutations in splicing factor genes
    Meeting Abstract

    Bewersdorf, J. P.; Stahl, M. F.; Taylor, J.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Kostantakis, V.; Lu, S. X.; Bourcier, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
    Journal Article

    Handa, S.; Lee, J. O.; Derkach, A.; Stone, R. M.; Saven, A.; Altman, J. K.; Grever, M. R.; Rai, K. R.; Shukla, M.; Vemuri, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling
    Journal Article

    Ganzel, C.; Sun, Z.; Baslan, T.; Zhang, Y.; Gönen, M.; Abdel-Wahab, O. I.; Racevskis, J.; Garrett-Bakelman, F.; Lowe, S. W.; Fernandez, H. F.; more...
    Leukemia Research (2022)

    Fulltext@MSK | Save
  • Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
    Journal Article

    Gigoux, M.; Holmström, M. O.; Zappasodi, R.; Park, J. J.; Pourpe, S.; Bozkus, C. C.; Mangarin, L. M. B.; Redmond, D.; Verma, S.; Schad, S.; more...
    Science Translational Medicine (2022)

    Fulltext@MSK | Save
  • Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
    Journal Article

    Chowell, D.; Yoo, S. K.; Valero, C.; Pastore, A.; Krishna, C.; Lee, M.; Hoen, D.; Shi, H.; Kelly, D. W.; Patel, N.; more...
    Nature Biotechnology (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save